Ethicon have the first and only sutures with Antibacterial Protection recommended for use in the NHS by NICE Medical Technologies guidance*[1]

Nearly 30% reduction in the risk of surgical site infection[1]

Potential environmental benefits to the NHS[1]

Cost-saving by an average of £13.62 saving per patient[1]

99.99%

MONOCRYL™ Plus reduces suture colonization by common SSI pathogens by 99% up to 99.99% as compared to non-antimicrobial sutures §†‡

Try our Interactive Tool to find out how you can Implement Ethicon Antibacterial Plus sutures →

*As of August 2021. §Tested in a 2-0 MONOCRYL™ Plus suture. †Log Reduction - Staphylococcus aureus 3.69, Staphylococcus epidermidis 1.84, MRSA 3.10, MRSE 4.92, Escherichia coli 4.54, Klebsiella pneumonia 3.64 - Log Reduction 1 = 90% reduction, Log Reduction 2 = 99% reduction, Log Reduction 3 = 99.9% reduction, Log Reduction 4 = 99.99% reduction. ‡The study was executed following protocol 100883589 and 100207824 Test Method for Bacterial Attachment rev 1. Based on a two-sample t-test, efficacy was demonstrated for Staphylococcus aureus (p-value 0.000), Staphylococcus epidermidis (p-value 0.000), MRSA (p-value 0.000), Escherichia coli (p-value 0.000), and Klebsiella pneumoniae (p-value 0.000) using 10% Trypticase Soy Broth (TSB). Efficacy was not observed for MRSE using the same conditions (10% TSB). MRSE is a slow growing bacterium and the recovery from control sutures was in the range of 3.5-4.24 log CFUs, which is 1-2 logs lower than other challenge bacteria, suggesting the media used (10% TSB) may not be suitable for this slow growing bacterium. It was thought that increasing concentration of TSB from 10- 50% would provide additional nutrients and hence support robust growth of the bacterium. The study was repeated with inoculum prepared in 50% TSB and results are reported (p-value 0.000). 1 © NICE 2021. MEDICAL TECHNOLOGY GUIDANCE: PLUS SUTURES FOR PREVENTING SURGICAL SITE INFECTION. Available from: nice.org.uk/guidance/MTG59 Accessed on: 28 June 2021. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

ETHICON
Johnson&Johnson SURGICAL TECHNOLOGIES

Ethicon have the first and only sutures with Antibacterial Protection recommended for use in the NHS by NICE Medical Technologies guidance*[1]

Nearly 30% reduction in the risk of surgical site infection[1]

Potential environmental benefits to the NHS[1]

Cost-saving by an average of £13.62 saving per patient[1]

99.99%

MONOCRYL™ Plus reduces suture colonization by common SSI pathogens by 99% up to 99.99% as compared to non-antimicrobial sutures §†‡

Try our Interactive Tool

Implement Plus Sutures

*As of August 2021. §Tested in a 2-0 MONOCRYL™ Plus suture.
†Log Reduction - Staphylococcus aureus 3.69, Staphylococcus epidermidis 1.84, MRSA 3.10, MRSE 4.92, Escherichia coli 4.54, Klebsiella pneumonia 3.64 - Log Reduction 1 = 90% reduction, Log Reduction 2 = 99% reduction, Log Reduction 3 = 99.9% reduction, Log Reduction 4 = 99.99% reduction. ‡The study was executed following protocol 100883589 and 100207824 Test Method for Bacterial Attachment rev 1. Based on a two-sample t-test, efficacy was demonstrated for Staphylococcus aureus (p-value 0.000), Staphylococcus epidermidis (p-value 0.000), MRSA (p-value 0.000), Escherichia coli (p-value 0.000), and Klebsiella pneumoniae (p-value 0.000) using 10% Trypticase Soy Broth (TSB). Efficacy was not observed for MRSE using the same conditions (10% TSB). MRSE is a slow growing bacterium and the recovery from control sutures was in the range of 3.5-4.24 log CFUs, which is 1-2 logs lower than other challenge bacteria, suggesting the media used (10% TSB) may not be suitable for this slow growing bacterium. It was thought that increasing concentration of TSB from 10- 50% would provide additional nutrients and hence support robust growth of the bacterium. The study was repeated with inoculum prepared in 50% TSB and results are reported (p-value 0.000). 1 © NICE 2021. MEDICAL TECHNOLOGY GUIDANCE:

ETHICON
Johnson & Johnson SURGICAL TECHNOLOGIES